Preclinical
Scientific Differentiation
Competitive Landscape Assessment
Patient Journey/Unmet Need
TAM
Target Product Profile
PIND/IND
Capital raise/IR
FIH/Phase 1
Integrated Development Plan
Input into late-stage/pivotal trial design (endpoints, comparator, PROs, subgroups, RWE concepts)
KOL identification and early SAB work
Patient advocacy strategy
TPP refinement
Capital raise/IR
Phase 2
Clinical Support/RWE, HEOR
Ongoing KOL/MSL scientific exchange
Patient advocacy strategy (continued)
Capital raise/IR
Phase 3
Prelaunch preparation:
Publication plan
KOL engagement at scale: Ad Boards, Speakers, COE mapping, and Society/Guideline engagement
Medical Communication
Payor access engagement
MSL
Transition phase - activities from Phase 3 continue and intensify
Commercial
Ongoing KOL/MSL scientific exchange
Medical Communication
Medical Information
RWE generation
Label expansion
Managed care engagement
Analytics & Agentive AI Partnership with
Learn more about our advanced digital and AI technologies
BPMS addresses the complexities of drug development
Full Clinical-Regulatory Consulting Services
Fractional CMO
Portfolio and indication prioritization
Integrated development plans
Clinical operations/Project Management
Regulatory meeting and document preparation
Due diligence
Safety evaluations
Investor relations support
Deep and broad expertise
Therapeutic Areas
Autoimmune
Bone disease
Immuno-Oncology
Rare Disease
Urology
Women’s Health
Molecular Modalities
Biologics
Cell & Gene Therapy
Drug-Device
Peptides
Small molecules
Vaccines
Full Service Medical Communications
Internally-aligned Scientific Platform
Publication strategy
Advocacy: identify, educate and enlist KOLs
Disease education
Congress presence
Advisory Boards and other live events
Preparation of payer dossiers
HEOR analyses and external control strategies
Omnichannel orchestration that drives consistent, personalized HCP engagement
